Dataset opportunity
Maslanka — 监管记录数据集机会
Maslanka 持有的中等规模监管记录数据集，可用于监管 RAG 和合规 Copilots。
Score
47.5
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
收购
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗器械监管事务市场 = 2025 年为 74.9 亿美元，复合年增长率为 9.69%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- ✨Signal
持续的研发和产品开发投资被提及为核心支柱
source ↗
Profile
Dataset profile
Type
监管记录数据集
Modality
文本
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — 许可权待澄清
Buyer persona
RegTech 和合规 AI 供应商
Maslanka 持有一个专门的监管记录数据集，其模态为文本，包含符合医疗器械法规 (MDR) 标准的专有医疗器械设计、专利和文档。这种结构化的工业数据和业务记录集合非常适合开发监管 RAG 系统，从而能够对复杂的合规和开发查询提供精确、基于证据的答案。
此类数据的商业价值在全球医疗器械监管事务市场中得到凸显，该市场在 2025 年的估值为74.9 亿美元，预计将以9.69% 的复合年增长率增长。[2] 尽管存在保密协议和专有设计等访问复杂性，但该数据集具有高度价值，因为它为构建人工智能工具以应对日益复杂且利润丰厚的医疗器械合规领域提供了稀有的现实基础。⚠ 尽职调查（有价值的数据，可协商访问）：数据涉及专有医疗器械设计和专利；受医疗器械法规 (MDR) 文档标准约束；可能与 OEM 合作伙伴签订保密协议以进行 kundenspezifische Entwicklungen · corporate: independent。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明了 Maslanka 拥有涵盖整个医疗器械产品生命周期的专有数据，从最初的研发和专利申请到内部制造。这个独特的高稀有度数据集对于寻求构建先进监管 RAG 模型的 RegTech 和合规 AI 供应商来说是一项关键资产。在预计到 2025 年将达到 74.9 亿美元的医疗器械监管市场中，这些数据通过提供训练复杂AI 解决方案以应对复杂合规路径所需的地面实况，提供了独特的竞争优势。
See dimension details ↓- Dataset Specificity78
主导的“监管”，医疗保健行业，2 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适用于监管 RAG
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand85
AI 买家需求旺盛，这得益于对专业数据的需求，以构建解决方案来应对复杂的医疗器械监管事务市场，该市场正以 9.69% 的复合年增长率扩张。[2]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility28
受限/未知
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility30
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License70
所有权=公司所有，许可=权利不明确
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 个数据胃口信号（1 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus70
盈余=中等 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit58
⚠ 审查 — 该公司制造和销售内窥镜的实体医疗器械，似乎不拥有“监管记录数据集”或任何其他数据驱动的产品。问题：该公司的核心业务是制造和销售实体商品（外科器械），而不是产生休眠数据的服务。[; 初步提示的描述“监管记录数据集机会”与公司实际的医疗器械制造业务完全不符；没有证据表明该公司拥有或生成任何重要数据集，除了标准的运营业务数据（销售、生产等）。
- Deep Qualification80
✓ 通过 — Maslanka 是一家医疗器械制造商，也为其他公司提供定制开发，这使得监管数据集的存在具有可能性，但其所有权在专有和客户拥有的知识产权之间混合。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Industrial data
这些证据表明拥有一个深厚的纵向研发数据档案，包括数十年的专利申请和持续的产品开发记录，这对于训练 AI 理解技术演进至关重要。
business_records
这些证据证实了详细记录客户特定产品开发与主要 MedTech 合作伙伴的记录的存在，提供了关于商业合作和市场标准的真实世界数据。
Regulatory records
这些证据展示了涵盖端到端制造过程的专有数据，从内部模具设计到成品医疗产品，这对于构建能够追溯产品完整合规历程的监管 RAG 系统至关重要。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Maslanka Regulatory Records — a Moderate regulatory records dataset (Text modality) in the healthcare domain. Primary AI use-case: Regulatory RAG. Market signal: Global Medical Device Regulatory Affairs market = $7.49B in 2025, CAGR 9.69% (source: Spherical Insights). Investment score 47.5/100 (confidence 0.49). Recommended action: Acquire.
From the marketplace
Explore live data opportunities
Porath — 法规记录数据集机会
View opportunity →mobilityNearnorthcustoms — 法规记录数据集机会
View opportunity →其他Roadnighttaylor — 监管记录数据集机会
View opportunity →